Schering Corporation

Cangmeng Yang

Neng-Yang Shih

Joseph A Kozlowski

Stuart B Rosenblum

Douglas Walsh Hobbs

Brian F McGuinness

Seong Heon Kim

Gopinadhan N Anilkumar

Guizhen Dong

Paul J Zavodny

Yuefei Shao

Chung-Her Jenh

Lisa Guise Zawacki

Carolyn Dilanni Carroll

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity

Growing community of inventors

Highland Park, NJ, United States of America

Cangmeng Yang